MPM Capital

Founded 1996
Founders Ansbert Gadicke Luke Evnin

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 256
Average round size
info
The average size of a deal this fund participated in
$36M
Portfolio companies 138
Rounds per year 10.24
Lead investments 53
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.46
Exits 84
Key employees 23
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Medical
Summary

MPM Capital is the famous VC, which was founded in 1996. The fund was located in North America if to be more exact in United States. The main department of described VC is located in the Cambridge.

We also calculated 24 valuable employees in our database.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the MPM Capital, startups are often financed by HealthCare Ventures, Domain Associates, Abingworth. The meaningful sponsors for the fund in investment in the same round are Astellas Venture Management, Venrock, Oxford Bioscience Partners. In the next rounds fund is usually obtained by Wellcome Trust, Venrock, HealthCare Ventures.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the most successful fund investment fields, there are Pharmaceutical, Medical. Among the various public portfolio startups of the fund, we may underline 23andMe, EndoGastric Solutions, Repare Therapeutics

Considering the real fund results, this VC is 10 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2003. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 7-12 deals per year. The increased amount of exits for fund were in 2014. The average startup value when the investment from MPM Capital is 100-500 millions dollars. Comparing to the other companies, this MPM Capital performs on 1 percentage points more the average number of lead investments.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Protego Biopharma

Biopharma
Biotechnology
Medical
Therapeutics
$51M19 Oct 2021 San Diego, California, United States

Frontier Medicines

Artificial Intelligence
Biotechnology
Pharmaceutical
$88M19 Jul 2021 San Francisco, California, United States

Entrada Therapeutics

Biotechnology
Emergency Medicine
Genetics
Health Care
Medical
$116M31 Mar 2021 Boston, Massachusetts, United States

Aktis Oncology

Biotechnology
Life Science
$72M18 Mar 2021 Boston, Massachusetts, United States

ElevateBio

Biotechnology
Genetics
Health Care
Therapeutics
$525M15 Mar 2021 Cambridge, Massachusetts, United States

Biotechnology
Medical
Pharmaceutical
Therapeutics
$80M24 Feb 2021 Cambridge, Massachusetts, United States

Umoja Biopharma

Biopharma
Biotechnology
Developer Platform
Information Technology
$53M18 Nov 2020 Seattle, Washington, United States

Trishula Therapeutics

Biotechnology
Life Science
Medical
26 Aug 2020 South San Francisco, California, United States

Dyne Therapeutics

Biotechnology
Health Care
Medical
Pharmaceutical
$115M10 Aug 2020 Cambridge, Massachusetts, United States
News
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.

Immunotherapy startup Umoja lands $210M, less than a year after raising $53M

– Umoja Biopharma, a Seattle-based immunotherapy company, raised $210m in Series B funding.
– The round was led by SoftBank Vision Fund 2 and Cormorant Asset Management.
– New investors included RTW Investments, LP, Temasek, Presight Capital, Caas Capital and SVB Leerink.
– Funds also came from existing investors: MPM Capital, DCVC Bio, Qiming Venture Partners USA, Casdin Capital, The Emerson Collective and Alexandria Venture Investments.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent MPM Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: